Introduction
============

Community-acquired pneumonia (CAP) remains a common and potentially life-threatening condition. Among patients hospitalised by CAP, the rates of severe CAP range from 6.6 to 16.7% \[[@B1]\].

The pathogens causing CAP may vary according to geographic area and underlying risk factors. Appropriate initial antimicrobial treatment has been repeatedly shown to be crucial for the outcome in severe infections. The knowledge of pathogen patterns causing CAP as the basis for the selection of such treatment is therefore crucial. Some studies have revealed that more than one causative microorganism was present in a considerable amount of cases. One of main problems for the studies on microbial aetiology in CAP is that not all microbiological tests are applied systematically for all patients. This limitation could possibly imply that the real frequency of polymicrobial aetiologies in main series is often underestimated.

The reported rates for polymicrobial aetiology, however, differ considerably between 5.7 and 38.4% \[[@B2]-[@B7]\]. The clinical significance of polymicrobial aetiology in CAP patients admitted to the ICU has not been specifically addressed. We therefore studied the prevalence, clinical characteristics and outcomes of severe CAP of polymicrobial aetiology in ICU patients.

Materials and methods
=====================

Ethics statement
----------------

The study was approved by the Ethics Committee of our institution, but written informed consent was waived due to the non-interventional design.

Study population
----------------

The present cohort included 362 consecutive adult patients with CAP admitted to the ICU within 24 hours of admission to the emergency department in an 850-bed tertiary care university hospital (Hospital Clinic of Barcelona, Spain) between January 2003 and December 2010. The decision for admission to an ICU was made by the attending physician in all cases.

Pneumonia was defined as a new pulmonary infiltrate found on the hospital admission chest radiograph with symptoms and signs of lower respiratory tract infection. We excluded patients with immunosuppression (for example, patients with neutropaenia after chemotherapy or bone marrow transplantation, patients with drug-induced immunosuppression as a result of solid-organ transplantation or corticosteroid (\> 10 mg/day) or cytotoxic therapy, and all HIV-infected patients) and healthcare-associated pneumonia patients.

Data collection and evaluation
------------------------------

The following parameters were recorded at admission: age, sex, tobacco use, alcohol and drug consumption, co-morbidities (chronic respiratory disease, including chronic obstructive pulmonary disease, asthma and bronchiectasis among others, diabetes mellitus, chronic cardiovascular disease, neurological disease, chronic renal disease and chronic liver disease), antibiotic treatment in the previous 30 days before hospital admission, treatment with corticosteroids, clinical symptoms and features (fever, cough, pleuritic chest pain, dyspnoea, mental confusion and aspiration), clinical signs (blood pressure, body temperature, respiratory rate and heart rate), arterial blood gas measurements, chest radiograph findings (number of lobes affected, pleural effusion and atelectasis), laboratory parameters (haemoglobin level, white blood cell count, platelet count, serum creatinine level, C-reactive protein level and other biochemical parameters), diagnostic procedures, empiric antibiotic therapy, ventilatory support, pulmonary complications (empyema, acute respiratory distress syndrome (ARDS) criteria, pleural effusion and surgical pleural draining) and other clinical events (cardiac arrhythmias, septic shock, and acute renal failure). The duration of treatment, length of hospital stay and 30-day in-hospital mortality were noted. We also calculated the pneumonia severity index (PSI) at admission \[[@B8]\].

Microbiological evaluation and diagnostic criteria
--------------------------------------------------

Microbiological examination was performed in sputum, urine, two samples of blood and nasopharyngeal swabs. Pleural puncture, tracheobronchial aspirates and bronchoalveolar lavage (BAL) fluid, when available, were collected. Conventional tests were used to evaluate the presence of bacterial, parasitic and fungal agents, and of respiratory viruses. Sputum, Bronchial aspirate sample (BAS) and BAL specimens were stained using the Gram and Ziehl-Neelsen methods for bacterial and mycobacteria detection, respectively. In BAL samples, the following additional stains were used: May-Grünwald Giemsa for fungal detection and cellular differential count, and Gomori methenamine silver for *Pneumocystis jirovecii*. Sputum and pleural fluid samples were qualitatively cultured for bacterial pathogens, fungi and mycobacteria. Bronchial aspirate sample (BAS) and BAL samples were homogenised and processed for quantitative culture by serial dilutions for bacterial pathogens; undiluted cultures for *Legionella*spp., fungi and mycobacteria were also carried out.

Nasopharyngeal swabs and BAL specimens were processed for antigen detection by immunofluorescence assay and for isolation of viruses in cell culture (influenza virus A, influenza virus B, human parainfluenza viruses 1 to 3, adenovirus and respiratory syncytial virus). In addition, two independent multiplex-nested RT-PCR assays able to detect from 1 to 10 copies of viral genomes were performed for the diagnostics of respiratory viruses. One RT-PCR assay detected influenza virus types A, B and C, respiratory syncytial viruses A and B, and adenovirus. Another RT-PCR assay studied parainfluenza viruses 1, 2, 3 and 4, coronaviruses 229E and OC43, rhinoviruses and enteroviruses. All positive results were subsequently confirmed by a second independent assay.

Sputum and blood samples were obtained for bacterial culture before the start of antibiotic therapy in the emergency department. Nasopharyngeal swab for respiratory virus detection and urine samples for *Streptococcus pneumoniae*and *Legionella pneumophila*antigen detection were obtained within 24 hours after hospital admission. Blood samples for serology of atypical pathogens and respiratory virus were taken at admission and within the third and sixth week thereafter.

Criteria for aetiological diagnosis
-----------------------------------

The aetiology was considered definite if one of the following criteria was met: blood culture positive (in the absence of an apparent extrapulmonary focus); positive bacterial culture of pleural fluid or transthoracic needle aspiration samples; elevated serum levels of IgM against *Chlamydophila pneumoniae*(≥ 1:64), *Coxiella burnetii*(≥ 1:80) and *Mycoplasma pneumoniae*(any positive titre); seroconversion (that is, a fourfold increase in IgG titres) for *C. pneumoniae*and *L. pneumophila*\> 1:128, *C. burnetii*\> 1:80 and respiratory viruses (influenza viruses A and B, parainfluenza viruses 1 to 3, respiratory syncytial virus and adenovirus); positive urinary antigen for *L. pneumophila*(Binax Now *L. pneumophila*urinary Antigen Test; Trinity Biotech, Bray, Ireland); positive urinary antigen for *S. pneumoniae*(Binax Now *S. pneumoniae*urinary Antigen Test; Emergo Europe, The Hague, The Netherlands); bacterial growth in cultures of tracheobronchial aspirates (≥ 10^5^cfu/ml), in a protected specimen brush (≥ 10^3^cfu/ml) and in BAL (≥ 10^4^cfu/ml); and detection of antigens by immunofluorescence assay plus virus isolation or detection by RT-PCR testing for respiratory virus (influenza viruses A and B, parainfluenza viruses 1 to 3, respiratory syncytial virus, rhinovirus and adenovirus).

The aetiology of pneumonia was classified as presumptive when a predominant microorganism was isolated from a purulent sample (leukocytes \> 25 per high-power microscopic field and few epithelial cells \< 10 per high-power microscopic field) and the findings of Gram staining were compatible. For the purpose of the present study, presumptive and definitive diagnostics were analysed together.

Definitions
-----------

Polymicrobial pneumonia was defined as pneumonia due to more than one pathogen. Severe CAP was defined when at least one major criterion or three minor criteria of the Infectious Disease Society of America/American Thoracic Society (IDSA/ATS) guidelines were present \[[@B9]\]. Appropriateness of empiric antibiotic treatment was defined when the isolated pathogens were susceptible *in vitro*to one of the antimicrobials administrated according to current European guidelines for microbiological susceptibility testing \[[@B10]\]. For *Pseudomonas aeruginosa*infection, adequate treatment needed a combination of two active antibiotics against the isolated strain.

Statistical analysis
--------------------

Categorical variables are described as frequencies and percentages, while continuous variables are presented as means and standard deviations, or as the median and interquartile range for data not normally distributed (Kolmogorov-Smirnov test). Categorical variables were compared with the chi-square test or Fisher\'s exact test where appropriate. Continuous variables were compared using the Student *t*test once normality was demonstrated; otherwise, the nonparametric Mann-Whitney U test was performed.

Univariate and multivariate logistic regression analyses were performed to identify variables predictive of patients with polymicrobial pneumonia (dependent variable). The independent variables analysed were: age, gender, smoking, alcohol consumption, previous antibiotic, influenza vaccine, pneumococcal vaccine, inhaled corticosteroids, systemic corticosteroids, chronic cardiovascular disease, chronic renal failure, diabetes mellitus, chronic liver disease, neurological disease, chronic pulmonary disease, fever, C-reactive protein level, white blood cell count, creatinine, PSI, multilobar infiltration, ARDS criteria, shock and mechanical ventilation. Univariate and multivariate logistic regression analyses were performed to predict 30-day mortality (dependent variable). The independent variables were the previous plus the number of aetiologies and adequacy of empirical treatment, with the exception of ARDS, shock and mechanical ventilation. Variables that showed a significant result univariately (*P*\< 0.1) were included in the multivariate logistic regression backward stepwise model. The Hosmer-Lemeshow goodness-of-fit test was performed to assess the overall fit of the model \[[@B11]\]. All tests were two-tailed and significance was set at 5%. All analyses were performed with SPSS version 16.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results
=======

Patients\' characteristics
--------------------------

During the study period, 2,200 patients were hospitalised with a diagnosis of CAP. Of these, 362 (16%) patients were admitted to the ICU. The main characteristics of patients and the outcome variables are shown in Table [1](#T1){ref-type="table"}.

###### 

Baseline characteristics of the whole population (*n*= 362) at admission to the ICU

  General characteristic                   Value
  ---------------------------------------- ---------------
  Demographics                             
   Age (years)                             63.4 ± 16.5
   Sex (male)                              232 (64%)
  Current smoking                          110 (31%)
  Current alcohol abuse                    77 (22%)
  Previous antibiotic                      67 (21%)
  Influenza vaccine                        140 (47%)
  Pneumococcal vaccine                     43 (14%)
  Inhaled corticosteroid                   89 (25%)
  Systemic corticosteroid                  23 (7%)
  Co-morbidity                             
   Chronic respiratory disease             134 (37%)
   Chronic obstructive pulmonary disease   59 (16%)
   Asthma                                  21 (6%)
   Bronchiectasis                          9 (3%)
   Other                                   45 (12%)
   Chronic cardiovascular disease          50 (14%)
   Diabetes mellitus                       70 (20%)
   Neurological disease                    68 (19%)
   Chronic renal disease                   23 (6%)
   Chronic liver disease                   23 (6%)
  Clinical findings                        
   Fever                                   281 (78%)
   Diastolic blood pressure (mmHg)         70 (21)
   Systolic blood pressure (mmHg)          120 (50)
  Laboratory findings                      
   Creatinine (mg/dl)                      1.1 (0.7)
   C-reactive protein level (mg/dl)        22.4 (20.8)
   White blood cell count (10^9^cells/l)   13.4 (10.5)
   Platelet count (10^9^platelets/l)       235.0 (127.0)
   Oxygen saturation (%)                   91.4 (8.5)
   PaO~2~/FIO~2~                           247.6 (99.5)
  Pneumonia severity index                 
   I to III                                96 (27%)
   IV                                      129 (37%)
   V                                       126 (36%)
  Bacteraemia                              63 (18%)
  Multilobar infiltration                  159 (44%)
  Pleural effusion                         79 (22%)
  Severe community-acquired pneumonia      201 (66%)
  Mechanical ventilation                   135 (44%)
  Septic shock                             72 (20%)
  ARDS criteria                            26 (7%)
  Length of hospital stay (days)           11.0 (9.0)
  Thirty-day mortality                     37 (10%)

Data presented as mean ± standard deviation, *n*(%) or median (interquartile range). ARDS, acute respiratory distress syndrome; PaO~2~/FIO~2~, arterial oxygen tension to inspired oxygen fraction ratio. Other respiratory diseases include sequelae of pulmonary tuberculosis, pulmonary hypertension and interstitial lung disease.

Among the 67 patients who had received antimicrobial treatment prior to hospital admission, the median duration of treatment was 2.8 days. The types of antibiotics received were: 25 (8%) β-lactams, 20 (6%) fluoroquinolones, six (2%) macrolides and 16 (5%) unknown.

Aetiology
---------

The specimens obtained included blood cultures from 330 (91%) patients, urine from 345 (95%) patients, acute and follow-up sera from 150 (41%) patients, sputum from 285 (79%) patients, bronchoscopically obtained lower respiratory secretions from 84 (23%) patients, pleural fluid in 62 (17%) patients, and nasopharyngeal and oropharyngeal swabs from 180 (50%) patients.

The aetiology of CAP could be established in 196 (54%) ICU patients. The proportion of patients with defined aetiology was higher in those with available lower respiratory tract samples, which included sputum and bronchoscopically obtained secretions (Table [2](#T2){ref-type="table"}). Patients with lower respiratory tract samples were more severe, assessed by higher PSI risk classes, more frequent septic shock, ARDS criteria and the need for mechanical ventilation.

###### 

Characteristics of patients with and without low respiratory tract samples

  Characteristic                        With samples (*n*= 86)   Without samples (*n*= 276)   *P*value
  ------------------------------------- ------------------------ ---------------------------- ----------
  Age (years)                           64.4 ± 16.7              63.0 ± 16.4                  0.39
  Sex (male)                            63 (73.3%)               169 (61.2%)                  
  Age ≥ 65 years                        47 (54.7)                149 (54)                     0.91
  Pneumonia severity index                                                                    0.049
   I to III                             13 (15.3%)               83 (31.2%)                   
   IV                                   26 (30.6%)               103 (38.7%)                  
   V                                    46(54.1%)                80 (30.1%)                   
  Bacteraemia                           18 (21.4%)               45 (17.4%)                   0.40
  Multilobar infiltration               46 (53.5%)               113 (40.9%)                  0.041
  Severe community-acquired pneumonia   66 (83.5%)               135 (59.2%)                  0.001
  Mechanical ventilation                60(81.1%)                75 (32.1%)                   0.001
  ARDS criteria                         17 (19.8%)               9 (33.3%)                    0.001
  Septic shock                          30 (34.9%)               42 (15.3%)                   0.001
  Length of hospital stay (days)        24.7 (20.7)              12.8 (10.5)                  \< 0.001
  Thirty-day mortality                  19 (22.1%)               18 (6.5%)                    0.001
  Aetiology                             60(70%)                  136 (49%)                    0.002
   *Streptococcus pneumoniae*           29 (48.3%)               93 (68.4%)                   
   *Staphylococcus aureus*              3 (5%)                   4 (2.9%)                     
   MRSA                                 8 (13.3%)                6 (4.4%)                     
   *Legionella pneumophila*             1 (1.7%)                 10 (7.4%)                    
   *Chlamydophila pneumophila*          1 (1.7%)                 5 (3.7%)                     
   *Haemophilus influenzae*             5 (8.3%)                 3 (2.2%)                     
   Virus                                10 (16.7%)               21(15.4%)                    
   *Coxiella burnetii*                  1 (1.7%)                 2 (1.5%)                     
   *Streptococcus viridans*             1 (1.7%)                 0                            
   *Mycoplasma pneumoniae*              4 (6.7%)                 2 (1.5%)                     
   *Pseudomonas aeruginosa*             7 (11.7%)                7 (5.1%)                     
   Gram-negative enteric bacilli        5 (8.3%)                 5 (3.7%)                     

Data presented as mean ± standard deviation, *n*(%) or median (interquartile range). ARDS, acute respiratory distress syndrome; MRSA, methicillin-resistant *Staphylococcus aureus*.

Monomicrobial infection was detected in 157 cases and polymicrobial infection in 39 cases (11% of the overall population and 20% of those with defined aetiology only), with two pathogens isolated in 33 cases and three pathogens in six cases. As shown in Table [3](#T3){ref-type="table"}, the most frequently identified pathogens were *S. pneumoniae*, respiratory viruses, *P. aeruginosa*, methicillin-resistant *Staphylococcus aureus*(MRSA), Gram-negative enteric bacilli (GNEB) and *L. pneumophila*.

###### 

Distribution of the causative microorganisms identified in 196 patients with community-acquired pneumonia

  Microorganism                      Monomicrobial aetiology (*n*= 157)   Polymicrobial aetiology (*n*= 39)   *P*value   Two pathogens (*n*= 33)   Three pathogens (*n*= 6)
  ---------------------------------- ------------------------------------ ----------------------------------- ---------- ------------------------- --------------------------
  *Streptococcus pneumoniae*         94 (60)                              28 (72)                             0.17       23 (70)                   5 (83)
  *Streptococcus pyogenes*           1 (1)                                1 (3)                               0.36       1 (3)                     \-
  *Streptococcus viridans*^a^        \-                                   1 (3)                               0.20       1 (3)                     \-
  *Staphylococcus aureus*(MSSA)      4 (3)                                3 (8)                               0.12       2 (6)                     1 (17)
  *Staphylococcus aureus*(MRSA)      5 (3)                                9 (23)                              \< 0.001   5 (15)                    4 (67)
  *Haemophilus influenzae*           4 (3)                                4 (10)                              0.029      3 (9)                     1 (17)
  *Moraxella catarrhalis*            1 (1)                                2 (5)                               0.041      1 (3)                     1 (17)
  Gram-negative enteric bacilli^b^   6 (4)                                7 (18)                              0.002      5 (15)                    2 (33)
  *Pseudomonas aeruginosa*           6 (4)                                8 (21)                              \< 0.001   6 (18)                    2 (33)
  Respiratory viruses                16 (10)                              15 (39)                             \< 0.001   14 (42)                   1 (17)
   Rhinovirus                        2 (1)                                2 (5)                               0.13       2 (6)                     \-
   Adenovirus                        1 (1)                                1 (3)                               0.36       1 (3)                     \-
   Respiratory syncitial virus       2 (1)                                2 (5)                               0.13       2 (6)                     \-
   Influenza virus A                 10 (6)                               9 (23)                              0.002      8 (24)                    1 (17)
   Influenza virus B                 1 (1)                                1 (3)                               0.36       1 (3)                     \-
   *Legionella pneumophila*          10 (6)                               1 (3)                               0.36       1 (3)                     \-
  Atypical                           10 (6)                               5 (13)                              0.18       4 (12)                    1 (17)
   *Mycoplasma pneumoniae*           4 (3)                                2 (5)                               0.40       2 (6)                     \-
   *Chlamydophila pneumoniae*        4 (3)                                2 (5)                               0.40       1 (3)                     1 (17)
   *Coxiella burnetii*               2 (1)                                1 (3)                               0.49       1 (3)                     \-

Data presented as *n*(%). Percentages refer to the total number of patients of each group (monomicrobial vs. polymicrobial). The most frequent combinations in cases with two pathogens were *S. pneumoniae*with respiratory viruses (11 cases), *P. aeruginosa*(three cases), and *H. influenzae*, Gram-negative enteric bacilli and atypicals in two cases each. The most frequent combination in cases with three pathogens was *S. pneumoniae*, Gram-negative enteric bacilli and methicillin-resistant *Staphylococcus aureus*(MRSA) in two cases. *P*value refers to a statistical comparison of cases with monomicrobial aetiology and polymicrobial aetiology. MSSA, methicillin-susceptible *Staphylococcus aureus*. ^a^*S. viridans*isolated from a pleural fluid specimen. ^b^Including *Escherichia coli, Klebsiella pneumoniae, Serratia marcescens*.

Comparison of the monomicrobial and polymicrobial aetiology
-----------------------------------------------------------

Patients with polymicrobial aetiology had previously received antibiotics less frequently, had a higher proportion of chronic respiratory and neurological diseases, less frequently presented fever at admission, had higher rates of PSI risk class V, had severe CAP according to the IDSA/ATS definition, and fulfilled ARDS criteria. The length of hospital stay and hospital mortality tended to be higher in these patients (Table [4](#T4){ref-type="table"}).

###### 

Characteristics of patients with defined aetiology, comparing monomicrobial and polymicrobial pneumonia

  Variable                                 Monomicrobial CAP (*n*= 157)   Polymicrobial CAP (*n*= 39)   *P*value
  ---------------------------------------- ------------------------------ ----------------------------- ----------
  Demographics                                                                                          
   Age (years)                             61.6 ± 17.7                    63.5 ± 14.1                   0.48
   Sex (male)                              106 (68%)                      23 (59%)                      0.31
   Current smoking                         46 (30%)                       13 (35%)                      0.53
   Current alcohol abuse                   32 (21%)                       12 (33%)                      0.11
  Previous antibiotic                      30 (22%)                       2 (7%)                        0.051
  Influenza vaccine                        50 (39%)                       9 (35%)                       0.65
  Pneumococcal vaccine                     20 (16%)                       2 (8%)                        0.29
  Inhaled corticosteroid                   29 (19%)                       11 (31%)                      0.10
  Systemic corticosteroid                  11 (7%)                        4 (12%)                       0.34
  Co-morbidity                                                                                          
   Chronic respiratory disease             50 (32%)                       21 (54%)                      0.011
   Chronic cardiovascular disease          21 (14%)                       1 (3%)                        0.068
   Diabetes mellitus                       26 (17%)                       4 (11%)                       0.40
   Neurological disease                    19 (12%)                       9 (25%)                       0.052
   Chronic renal disease                   10 (7%)                        2 (6%)                        0.84
   Chronic liver disease                   9 (6%)                         5 (13%)                       0.11
  Clinical findings                                                                                     
   Fever                                   132 (84%)                      27 (69%)                      0.034
   Diastolic blood pressure (mmHg)         68.0 (20.0)                    70.0 (22.0)                   0.38
   Systolic blood pressure (mmHg)          120.0 (48.0)                   121.0 (63.0)                  0.23
  Laboratory findings                                                                                   
   Creatinine (mg/dl)                      1.2 (0.8)                      1.3 (0.7)                     0.57
   C-reactive protein level (mg/dl)        25.2 (20.3)                    26.5 (11.6)                   0.24
   White blood cell count (10^9^cells/l)   13.1 (12.1)                    9.5 (13.4)                    0.019
   Oxygen saturation (%)                   93 (7.9)                       92.0 (7.3)                    0.78
   PaO~2~/FIO~2~                           254.3 (84.6)                   247.6 (104.8)                 0.38
  Inappropriate empirical treatment        15 (10%)                       15 (39%)                      \< 0.001
  Pneumonia severity index                                                                              
   I to III                                44 (29%)                       10 (28%)                      0.89
   IV                                      60 (40%)                       8 (22%)                       0.053
   V                                       48 (32%)                       18 (50%)                      0.037
  Severe CAP                               94 (68%)                       31 (86%)                      0.029
  Bacteraemia                              47 (32%)                       14 (39%)                      0.45
  Multilobar infiltration                  74 (47%)                       27 (69%)                      0.013
  Pleural effusion                         36 (23%)                       9 (24%)                       0.94
  Mechanical ventilation                   60 (43%)                       21 (62%)                      0.047
  ARDS criteria                            6 (4%)                         12 (31%)                      \< 0.001
  Septic shock                             38 (24%)                       14 (36%)                      0.14
  Length of hospital stay (days)           12.0 (11.0)                    15.0 (10.0)                   0.082
  Thirty-day mortality                     17 (11%)                       8 (21%)                       0.10

Data presented as mean ± standard deviation, *n*(%) or median (interquartile range). ARDS, acute respiratory distress syndrome; CAP, community-acquired pneumonia; PaO~2~/FIO~2~, arterial oxygen tension to inspired oxygen fraction ratio. Other respiratory diseases include sequelae of pulmonary tuberculosis, pulmonary hypertension and interstitial lung disease.

As regards the aetiologic pathogens, the proportion of respiratory viruses-particularly influenza A, MRSA, *P. aeruginosa*, GNEB, *Haemophilus influenzae*and *Moraxella catarrhalis*- were more frequently isolated in patients with polymicrobial pneumonia, without differences in the remaining pathogens (Table [3](#T3){ref-type="table"}).

Empirical antibiotic therapy
----------------------------

Data on antibiotic treatment were available in 347 (96%) patients. The most frequent regimens were fluoroquinolones plus β-lactam (*n*= 217, 63%), β-lactam plus macrolide (*n*= 73, 21%), fluoroquinolone monotherapy (*n*= 39, 11%) and β-lactam monotherapy (*n*= 18, 5%). These regimens were similarly administered in patients with monomicrobial or polymicrobial aetiology.

The empirical antibiotic treatment was more frequently inappropriate in patients from the polymicrobial aetiology group (Table [4](#T4){ref-type="table"}). When respiratory viruses were not taken into account, the pathogens most frequently associated with inadequate treatment were MRSA in 10 cases, and *S. pneumoniae, P. aeruginosa*and GNEB in nine cases each. None of our patients received antiviral therapy.

Predictors of polymicrobial aetiology
-------------------------------------

Several variables were significantly associated with polymicrobial pneumonia in the univariate logistic regression analyses (Table [5](#T5){ref-type="table"}). Among these variables, chronic respiratory disease and ARDS criteria at hospital admission were independent predictors of polymicrobial aetiology in the multivariate analysis.

###### 

Univariate and multivariate logistic regression analyses of predictors of polymicrobial pneumonia

  Variable                      Univariate analysis                   Multivariate analysis^a^                           
  ----------------------------- --------------------- --------------- -------------------------- ------- --------------- ----------
  Previous antibiotic           0.25                  0.06 to 1.11    0.068                      **-**   **-**           **-**
  Neurological disease          2.39                  0.98 to 5.83    0.057                                              
  Chronic respiratory disease   2.50                  1.22 to 5.10    0.012                      2.86    1.31 to 6.25    0.008
  Fever                         0.43                  0.19 to 0.95    0.037                      \-      \-              \-
  WBC (+10 × 10^9^cells/l)^b^   0.61                  0.38 to 0.98    0.041                      **-**   ***-***         **-**
  Multilobar infiltration       2.52                  1.19 to 5.34    0.015                      \-      \-              \-
  Mechanical ventilation        2.15                  1.00 to 4.64    0.050                      \-      \-              **-**
  ARDS criteria                 11.11                 3.84 to 32.14   \< 0.001                   12.31   4.08 to 37.12   \< 0.001

ARDS, acute respiratory distress syndrome; CI, confidence interval; WBC, white blood cells. ^a^Hosmer-Lemeshow goodness-of-fit test, *P*= 0.55. ^b^Increase by 10 × 10^9^cells/l.

Predictors of hospital mortality
--------------------------------

The univariate logistic regression analyses revealed several variables significantly associated with hospital mortality (Table [6](#T6){ref-type="table"}). Although polymicrobial pneumonia (that is, two or more pathogens identified) was associated with increased mortality compared with the absence of defined aetiology, the differences between monomicrobial and polymicrobial aetiology were not significant, as shown in Table [4](#T4){ref-type="table"}.

###### 

Univariate and multivariate logistic regression analysis of predictors of mortality

  Variable                            Univariate analysis                   Multivariate analysis^a^                           
  ----------------------------------- --------------------- --------------- -------------------------- ------- --------------- ----------
  Age ≥ 65 years                      2.49                  1.17 to 5.32    0.018                      3.06    1.27 to 7.41    0.013
  Diabetes mellitus                   2.25                  1.06 to 4.76    0.034                      \-      \-              \-
  Neurological disease                2.04                  0.95 to 4.38    0.068                      2.63    1.07 to 6.48    0.036
  Chronic liver disease               5.63                  2.20 to 14.39   \< 0.001                   8.99    2.91 to 27.77   \< 0.001
  Fever                               0.49                  0.24 to 1.01    0.053                      \-      \-              \-
  Pneumonia severity index IV to V    4.77                  1.43 to 15.91   0.011                      \-      \-              \-
  Multilobar infiltration             2.28                  1.13 to 4.60    0.021                      \-      \-              \-
  Number of pathogens identified^b^                                         0.055                      \-      \-              \-
   None                               1                     \-              \-                                                 
   Monomicrobial                      1.56                  0.72 to 3.38    0.26                       \-      \-              \-
   Polymicrobial                      3.31                  1.25 to 8.77    0.016                      \-      \-              \-
  Inappropriate empiric treatment     11.23                 4.44 to 28.38   \< 0.001                   10.79   3.97 to 29.30   \< 0.001

^a^Hosmer-Lemeshow goodness-of-fit test, *P*= 0.81. ^b^The *P*value corresponds to differences between the three groups (none, one or more than one pathogen). The odds ratio and 95% confidence interval (CI) of monomicrobial and polymicrobial pneumonia are related to cases with no pathogen identified.

Among these variables, age ≥ 65 years, neurological disease, chronic liver disease and inappropriate antimicrobial treatment were independently associated with increased hospital mortality in the multivariate analysis.

Discussion
==========

Polymicrobial aetiology was found in 11% of all patients with CAP admitted to the ICU, 20% considering those with defined aetiology only. Although *S. pneumoniae*was the most frequent pathogen in both groups, we found MRSA, *P. aeruginosa*, GNEB, *H. influenzae, M. catarrhalis*and respiratory viruses more frequently identified in polymicrobial pneumonia than in monomicrobial pneumonia. Chronic respiratory disease and ARDS criteria were independent predictors of polymicrobial aetiology. Although an independent predictor of hospital mortality such as inappropriate treatment was more frequent in the polymicrobial aetiology group, the trend for higher hospital mortality in patients from this group was not statistically significant.

In general populations of hospitalised patients with CAP, we have previously reported lower rates of polymicrobial pneumonia (5%) \[[@B3],[@B12]\] than in this series of ICU patients. Other studies on patients with CAP found 5.7% and 38.4% rates of polymicrobial aetiology in their series \[[@B4],[@B5]\]. These wide variations might be explained by differences in the populations studied, epidemiological settings, rate of antimicrobial pretreatment, microbiological workup and definitions of aetiology. A typical limitation of many studies dealing with microbial aetiology in CAP is that not all microbiological tests are applied systematically for all patients. This issue means that the real frequency of polymicrobial aetiologies could possibly be higher if a complete microbiological investigation was performed in all cases. In view of these methodological problems, it seems difficult to indicate precisely the extent of the problem of polymicrobial aetiology. Analysing the potential impact of polymicrobial aetiology is therefore more important, particularly in the most severely ill patients and in those at highest risk of death.

*S. pneumoniae*was not only the most frequent pathogen but also by far the most frequent co-pathogen in polymicrobial infections. This finding underlines the importance of pneumococcal coverage in any initial antimicrobial treatment regimen. The most frequent polymicrobial pattern was *S. pneumoniae*and viral infection, particularly influenza virus. Pneumococci have been identified as the most frequent bacterial superinfection in both seasonal \[[@B13]\] and novel H1N1 \[[@B14],[@B15]\] influenza virus-associated pneumonia.

Interestingly, whereas *S. pneumoniae*was by far the most frequent single pathogen, the rate of this pathogen was similar among patients with monomicrobial aetiology and those with polymicrobial aetiology. Among the pathogens more frequently identified in polymicrobial pneumonia, respiratory viruses were the most frequent. We did not find that polymicrobial aetiology was associated with higher mortality. Viruses were the most frequent microorganisms associated with polymicrobial aetiology. Except for influenza A H1N1, viruses are not a cause of excess mortality-as recently pointed out by two recent studies \[[@B13],[@B16]\]. The role of viruses in the aetiology of pneumonia is unclear, since they may be regarded either as primary infection or, with bacteria, as representing superinfection \[[@B17]\]. None of our patients received antiviral treatment. We feel that at least during the influenza season, however, patients could benefit from antiviral treatment.

The role of MRSA in CAP is limited in Europe, even if patients meeting criteria for healthcare-associated pneumonia remain included \[[@B18]\]. Although for our series we excluded patients with healthcare-associated pneumonia, the frequent association of this pathogen with severe underlying illness \[[@B19]\] may explain the higher rate of this pathogen in the polymicrobial aetiology group, since these patients were more severe at admission than those with monomicrobial aetiology. The exact role of MRSA in polymicrobial CAP is difficult to assess, however, because even a high bacterial load of MRSA may still represent colonisation rather than infection \[[@B20]\]. The higher rate of *P. aeruginosa*and GNEB in polymicrobial pneumonia may also be related to the higher rate of chronic respiratory diseases in this group, since identification of these pathogens occurs more frequently in those with chronic lung disease \[[@B21]\]. As for MRSA, the identification of *P. aeruginosa*does not necessarily mean this is the causative pathogen of acute exacerbation in all chronic obstructive pulmonary disease patients colonised by the pathogen \[[@B22]\], and similarly MRSA eventually may represent colonisation rather than infection in patients with pneumonia.

We identified chronic respiratory disease and ARDS criteria as independent predictors of polymicrobial aetiology. In chronic obstructive pulmonary disease, this finding can be explained by the previous colonisation of different bacteria these patients may have in their lower airways. On the contrary, ARDS may be the consequence of a mixed infection with higher pulmonary insult. In both chronic obstructive pulmonary disease and ARDS with severe CAP, our recommendation is to give a broad empirical antibiotic treatment from the beginning of therapy because mixed infections are more frequent \[[@B23],[@B24]\].

A relevant issue in polymicrobial aetiology of severe CAP refers to its potential prognostic implications. We found a strong association between polymicrobial aetiology and initial inappropriate antimicrobial treatment, which in turn was an independent predictor of increased hospital mortality. Inappropriate empiric treatment has already been associated with poor outcome in patients with severe infections \[[@B25],[@B26]\]. Although crude mortality was near double in patients with polymicrobial aetiology, this difference did not reach statistical significance-probably due to the insufficient number of patients included. These results indicate that the impact of initial inappropriate antimicrobial treatment is crucial for survival, and that polymicrobial aetiology is an important determinant for such inappropriateness.

To the best of our knowledge, this is the first study addressing the issue of multiple aetiologies of CAP in a large population of ICU patients. We decided to include all patients admitted to the ICU regardless of whether they met IDSA/ATS severity criteria. We think that clinical decisions for ICU admission may be valid, while the IDSA/ATS severity criteria have proven to be overly sensitive \[[@B1],[@B12]\].

Several limitations have to be addressed. First, the complete diagnostic workup and microbiological sampling could not be applied in every patient. Second, the true incidence of polymicrobial aetiology may be underestimated since 21% patients had received prior antimicrobial treatment. Finally, viral infections may have been missed since paired serology is frequently not available in nonsurvivors. We did not include molecular techniques such as PCR for bacterial detection. We believe that the systematic use of qualitative and quantitative PCR for the diagnosis of respiratory infections may increase substantially the number of identified bacterial pathogens \[[@B7],[@B27]\]. Moreover, these new techniques could play a crucial role in the determination of the clinical impact of polymicrobial aetiology in CAP. Unfortunately, the use of molecular techniques is not yet part of the routine diagnostic workup in CAP.

Conclusions
===========

Polymicrobial aetiology is a frequent finding in patients with CAP admitted to the ICU. Our data support the potential implication of polymicrobial pneumonia in the outcome of patients related to an increased risk of inappropriate antimicrobial treatment, and suggests the importance of an extensive microbiological testing in very severe CAP patients since the CAP may be caused by more than one aetiology.

The most important clinical implication of the identified predictors of polymicrobial aetiology is to emphasise the use of broad-spectrum antimicrobial treatment in these groups of patients.

Key messages
============

• Polymicrobial aetiology is frequent among patients with CAP admitted to the ICU and may result in inappropriate empiric antimicrobial treatment.

• Polymicrobial aetiology of CAP should be suspected in the presence of chronic respiratory disease or criteria for ARDS.

• If antimicrobial treatment is appropriate, polymicrobial aetiology does not result in increased hospital mortality from severe CAP.
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